HLA-Engineered iPSC-Derived Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Mice
Cells · 2026
DOI: 10.3390/cells15191777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Ze Wei und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing …. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Osteoarthritis, Induced Pluripotent Stem Cells, Mesenchymal Stem Cell Transplantation. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Osteoarthritis (OA) is one of the most prevalent degenerative joint diseases, and there is no approved pharmacological therapy that can reliably reverse cartilage degeneration or restore cartilage structure. Allogeneic mesenchymal stromal cells (MSCs) have shown therapeutic potential for OA, but inflammatory conditions can enhance HLA expression and increase allogeneic immune recognition risk. Here, we generated B2M and CIITA double-knockout induced pluripotent stem cells (dKO-iPSCs) using CRISPR/Cas9 and subsequently differentiated them into dKO-iMSCs. B2M/CIITA double-knockout did not affect iPSC pluripotency, karyotype, or teratoma formation. dKO-iMSCs retained characteristic MSC phenotypes, exhibited greater proliferative capacity than tissue-derived MSCs, and could be expanded to passage 18. Notably, HLA-ABC and HLA-DR expression remained undetectable in dKO-iMSCs even after IFN-γ stimulation. In co-culture assays with PHA-L-stimulated allogeneic PBMCs, dKO-iMSCs suppressed PBMC and T-cell proliferation as effectively as wild-type iMSCs, indicating preservation of their immunomodulatory activity. Intra-articular administration of dKO-iMSCs significantly reduced cartilage degeneration in the destabilization of the medial meniscus (DMM) mouse model of OA. The treatment showed greater therapeutic efficacy than wild-type iMSCs and tissue-derived MSCs and did not cause evident systemic organ toxicity. Single-cell RNA sequencing of BM-MSCs and dKO-iMSCs after in vitro IFN-γ stimulation revealed enhanced extracellular matrix-associated cell–cell communication and markedly reduced IL1B expression in dKO-iMSCs, indicating a less pro-inflammatory and more matrix-supportive cellular state under inflammatory conditions. Collectively, B2M/CIITA double-knockout enables sustained reduction in HLA expression while preserving the MSC phenotype and immunomodulatory activity, and enhances the therapeutic efficacy of iMSCs in the mouse OA model, providing a potential strategy for developing iPSC-derived MSCs with reduced HLA expression for allogeneic cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Stem Cell Facility, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Exploratory Laboratory, Gan & Lee Pharmaceuticals, Beijing 101109, China.
- State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 102602, China.
ORCID-Profile: Zhifa Zheng
Förderung
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
- CAMS Innovation Fund for Medical Sciences
- Beijing Municipal Science and Technology Commission
- The Strategic Research and Consulting Project of the Chinese Academy of Engineering
- Independent Research Fund of the State Key Laboratory of Complex, Severe, and Rare Diseases
- the Fundamental Research Funds for the Central Universities, Peking Union Medical College
- Beijing Municipal Science & Technology Commission
Zitieren
APA
Wei, Z., Gan, T., Liang, A., Liu, S., Hao, J., Zou, W., Li, L., Mu, X., Han, H., Ma, W., Xing, J., Wei, Y., Fan, H., Liu, L., Liu, F., Zheng, Z., Wu, Z., & Zhao, L. (2026). HLA-Engineered iPSC-Derived Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Mice. Cells. https://doi.org/10.3390/cells15191777
Vancouver
Wei Z, Gan T, Liang A, Liu S, Hao J, Zou W, et al. HLA-Engineered iPSC-Derived Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Mice. Cells. 2026. doi:10.3390/cells15191777
BibTeX
@article{Wei2026,
author = {Wei, Ze and Gan, Tian and Liang, Annan and Liu, Su and Hao, Jing and Zou, Wei and Li, Lun and Mu, Xuemeng and Han, Huitian and Ma, Wenjing and Xing, Jinyi and Wei, Yifan and Fan, Hao and Liu, Lijin and Liu, Fei and Zheng, Zhifa and Wu, Zhihong and Zhao, Lina},
title = {HLA-Engineered iPSC-Derived Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Mice},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15191777}
}
EUVIMED